MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022)

MoonLake Immunotherapeutics' Long-Term Investments history runs 3 years deep, the most recent figure standing at $115.1 million for Q1 2022.

• In Q1 2022, Long-Term Investments changed 0.02% year-over-year to $115.1 million; the TTM figure through Mar 2022 stood at $115.1 million (changed 0.02% YoY), while the FY2021 annual figure was $115.0 million, changed 0.02% from the prior year.
• Long-Term Investments was $115.1 million for Q1 2022 at MoonLake Immunotherapeutics, roughly flat from $115.0 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $115.1 million in Q1 2022 to a low of $115.0 million in Q4 2020.
• Historically, Long-Term Investments has averaged $115.0 million across 3 years, with a median of $115.0 million in 2021.
• The sharpest annual moves came in 2021 and 2022: Long-Term Investments rose 0.02% in 2021, then climbed 0.02% in 2022.
• A 3-year view of Long-Term Investments shows it stood at $115.0 million in 2020, then increased by 0.02% to $115.0 million in 2021, then rose by 0.01% to $115.1 million in 2022.
• The last three Long-Term Investments figures came in at $115.1 million (Q1 2022), $115.0 million (Q4 2021), and $115.0 million (Q3 2021), per Business Quant data.